Do analysts recommend INMB or RNAC?

Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 362.41%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Cartesian Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Do analysts prefer INMB or ADAG?

Adagene has a consensus target price of $8.67, indicating a potential upside of 214.01%. Given Adagene's stronger consensus rating and higher probable upside, analysts clearly believe Adagene is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Adagene 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has better earnings & valuation, INMB or ADAG?

Adagene has higher revenue and earnings than INmune Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,048.95 -$45.93M -$0.67 N/A Adagene $7.67M 23.77 -$17.61M N/A N/A

Is INMB or ADAG more profitable?

Adagene's return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Adagene N/A N/A N/A

Does the media prefer INMB or ADAG?

In the previous week, Adagene had 2 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for Adagene and 2 mentions for INmune Bio. Adagene's average media sentiment score of 0.80 beat INmune Bio's score of 0.00 indicating that Adagene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adagene 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INMB or WHWK?

Whitehawk Therapeutics has a consensus target price of $8.33, suggesting a potential upside of 136.74%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Whitehawk Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Whitehawk Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Is INMB or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Whitehawk Therapeutics N/A -53.89% -49.97%

Does the media prefer INMB or WHWK?

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Whitehawk Therapeutics and 2 mentions for INmune Bio. Whitehawk Therapeutics' average media sentiment score of 0.15 beat INmune Bio's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate INMB or ALEC?

Alector has a consensus target price of $3.40, indicating a potential upside of 63.46%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Alector 2 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.11

Which has stronger earnings & valuation, INMB or ALEC?

INmune Bio has higher earnings, but lower revenue than Alector. INmune Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,048.95 -$45.93M -$0.67 N/A Alector $21.05M 11.03 -$142.93M -$1.10 N/A

Is INMB or ALEC more profitable?

INmune Bio has a net margin of 0.00% compared to Alector's net margin of -850.13%. INmune Bio's return on equity of -82.87% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Alector -850.13% -531.03% -44.00%

Does the media prefer INMB or ALEC?

In the previous week, Alector had 18 more articles in the media than INmune Bio. MarketBeat recorded 20 mentions for Alector and 2 mentions for INmune Bio. Alector's average media sentiment score of 0.53 beat INmune Bio's score of 0.00 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 2 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend INMB or ELDN?

Eledon Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 303.23%. Given Eledon Pharmaceuticals' higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Eledon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is INMB or ELDN more profitable?

INmune Bio's return on equity of -82.87% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media refer more to INMB or ELDN?

In the previous week, INmune Bio and INmune Bio both had 2 articles in the media. INmune Bio's average media sentiment score of 0.00 equaled Eledon Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

INmune Bio (INMB) Competitors

$1.89 +0.06 (+3.28%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.90 +0.01 (+0.26%)

As of 10/9/2026 07:30 PM Eastern

Compare

INMB vs. RNAC, ADAG, WHWK, ALEC, and ELDN

Should you buy INmune Bio stock or one of its competitors? INmune Bio's main competitors and comparable companies include Cartesian Therapeutics (RNAC), Adagene (ADAG), Whitehawk Therapeutics (WHWK), Alector (ALEC), and Eledon Pharmaceuticals (ELDN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does INmune Bio compare to Cartesian Therapeutics?

INmune Bio (NASDAQ:INMB) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 362.41%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

INmune Bio has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

INmune Bio has higher earnings, but lower revenue than Cartesian Therapeutics. INmune Bio is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,048.95	-$45.93M	-$0.67	N/A
Cartesian Therapeutics	$2.80M	76.17	-$130.30M	-$5.94	N/A

INmune Bio has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, INmune Bio had 1 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.15 beat INmune Bio's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Neutral
Cartesian Therapeutics	Neutral

Summary

Cartesian Therapeutics beats INmune Bio on 10 of the 17 factors compared between the two stocks.

How does INmune Bio compare to Adagene?

INmune Bio (NASDAQ:INMB) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

INmune Bio has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Adagene has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Adagene has a consensus target price of $8.67, indicating a potential upside of 214.01%. Given Adagene's stronger consensus rating and higher probable upside, analysts clearly believe Adagene is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Adagene has higher revenue and earnings than INmune Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,048.95	-$45.93M	-$0.67	N/A
Adagene	$7.67M	23.77	-$17.61M	N/A	N/A

In the previous week, Adagene had 2 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for Adagene and 2 mentions for INmune Bio. Adagene's average media sentiment score of 0.80 beat INmune Bio's score of 0.00 indicating that Adagene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adagene	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene's return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Adagene	N/A	N/A	N/A

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Adagene beats INmune Bio on 9 of the 13 factors compared between the two stocks.

How does INmune Bio compare to Whitehawk Therapeutics?

INmune Bio (NASDAQ:INMB) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Whitehawk Therapeutics' return on equity of -53.89% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Whitehawk Therapeutics has lower revenue, but higher earnings than INmune Bio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,048.95	-$45.93M	-$0.67	N/A
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.12	N/A

INmune Bio has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Whitehawk Therapeutics and 2 mentions for INmune Bio. Whitehawk Therapeutics' average media sentiment score of 0.15 beat INmune Bio's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Whitehawk Therapeutics has a consensus target price of $8.33, suggesting a potential upside of 136.74%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Whitehawk Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Whitehawk Therapeutics beats INmune Bio on 11 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Alector?

INmune Bio (NASDAQ:INMB) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

INmune Bio has higher earnings, but lower revenue than Alector. INmune Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,048.95	-$45.93M	-$0.67	N/A
Alector	$21.05M	11.03	-$142.93M	-$1.10	N/A

Alector has a consensus target price of $3.40, indicating a potential upside of 63.46%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Alector	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

INmune Bio has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Alector has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

INmune Bio has a net margin of 0.00% compared to Alector's net margin of -850.13%. INmune Bio's return on equity of -82.87% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Alector	-850.13%	-531.03%	-44.00%

In the previous week, Alector had 18 more articles in the media than INmune Bio. MarketBeat recorded 20 mentions for Alector and 2 mentions for INmune Bio. Alector's average media sentiment score of 0.53 beat INmune Bio's score of 0.00 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	2 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

INmune Bio beats Alector on 9 of the 17 factors compared between the two stocks.

How does INmune Bio compare to Eledon Pharmaceuticals?

INmune Bio (NASDAQ:INMB) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Eledon Pharmaceuticals has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,048.95	-$45.93M	-$0.67	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

INmune Bio has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

INmune Bio's return on equity of -82.87% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Eledon Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 303.23%. Given Eledon Pharmaceuticals' higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, INmune Bio and INmune Bio both had 2 articles in the media. INmune Bio's average media sentiment score of 0.00 equaled Eledon Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

INmune Bio beats Eledon Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$50.79M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-2.82	13.42	274.15	26.16
Price / Sales	1,048.95	1,234.32	589.97	94.50
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	2.15	17.17	11.21	6.34
Net Income	-$45.93M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-2.07%	-1.33%	-0.90%	-1.41%
1 Month Performance	-18.18%	-8.44%	-4.44%	-3.48%
1 Year Performance	1.61%	14.02%	6.96%	1.16%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	0.2776 of 5 stars	$1.89 +3.3%	N/A	-4.5%	$50.79M	$50K	N/A	21	Gap Down
RNAC Cartesian Therapeutics	1.9501 of 5 stars	$7.18 -0.5%	$32.60 +354.3%	-30.2%	$217.65M	$2.80M	N/A	75
ADAG Adagene	4.0225 of 5 stars	$3.21 +0.2%	$8.67 +170.4%	+41.5%	$211.69M	$7.67M	N/A	128
WHWK Whitehawk Therapeutics	2.7325 of 5 stars	$3.70 -1.7%	$8.20 +121.9%	+62.2%	$210.65M	$7.14M	N/A	23
ALEC Alector	2.1917 of 5 stars	$1.88 -2.3%	$3.63 +93.3%	-33.8%	$209.36M	$21.05M	N/A	103	Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. RNAC, ADAG, WHWK, ALEC, and ELDN

How does INmune Bio compare to Cartesian Therapeutics?

Summary

How does INmune Bio compare to Adagene?

Summary

How does INmune Bio compare to Whitehawk Therapeutics?

Summary

How does INmune Bio compare to Alector?

Summary

How does INmune Bio compare to Eledon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. RNAC, ADAG, WHWK, ALEC, and ELDN

How does INmune Bio compare to Cartesian Therapeutics?

Do analysts recommend INMB or RNAC?

Is INMB or RNAC more profitable?

Which has preferable earnings & valuation, INMB or RNAC?

Which has more volatility & risk, INMB or RNAC?

Do insiders and institutionals hold more shares of INMB or RNAC?

Does the media prefer INMB or RNAC?

Summary

How does INmune Bio compare to Adagene?

Which has more volatility and risk, INMB or ADAG?

Do analysts prefer INMB or ADAG?

Which has better earnings & valuation, INMB or ADAG?

Does the media prefer INMB or ADAG?

Is INMB or ADAG more profitable?

Do insiders & institutionals believe in INMB or ADAG?

Summary

How does INmune Bio compare to Whitehawk Therapeutics?

Is INMB or WHWK more profitable?

Which has better valuation and earnings, INMB or WHWK?

Which has more volatility and risk, INMB or WHWK?

Does the media prefer INMB or WHWK?

Do analysts rate INMB or WHWK?

Do institutionals and insiders have more ownership in INMB or WHWK?

Summary

How does INmune Bio compare to Alector?

Which has stronger earnings & valuation, INMB or ALEC?

Do analysts rate INMB or ALEC?

Do institutionals & insiders hold more shares of INMB or ALEC?

Which has more volatility & risk, INMB or ALEC?

Is INMB or ALEC more profitable?

Does the media prefer INMB or ALEC?

Summary

How does INmune Bio compare to Eledon Pharmaceuticals?

Which has higher earnings & valuation, INMB or ELDN?

Which has more risk and volatility, INMB or ELDN?

Is INMB or ELDN more profitable?

Do analysts recommend INMB or ELDN?

Does the media refer more to INMB or ELDN?

Do insiders and institutionals hold more shares of INMB or ELDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools